News & Events – Ysios Capital

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

Swiss Biotech Day 2026
4 May - 5 May, 2026
Zurich
Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
20 -22 May, 2026
Malta
CFO Forum
21 - 22 May, 2026
Málaga
BIOSPAIN
29 September - 1 October, 2026
Bilbao

Type:

Year:

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Clinical trial in patients anticipated to begin in 2025

Ysios Capital y Andbank se alían para lanzar el fondo Telescope Biotech Fund<

Ysios Capital y Andbank se alían para lanzar el fondo Telescope Biotech Fund

El fondo invierte en compañías cotizadas del sector biotecnológico, con foco en EE.UU.

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease<

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Phase 1/2 ASTRA study set to begin in the first half of 2025.

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy<

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025.

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027<

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society

FDA granted RMAT designation in 2024; pivotal trial planned for 2H 2025

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing<

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline<

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences<

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials

Ysios Capital ESG Report<

Ysios Capital ESG Report

A milestone reflecting the firm’s deep commitment to responsible and sustainable investment.

« Previous 1 … 10 11 12 13 14 … 77 Next »